COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

HIV Clinical Trial

Official title:

Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04958889
• Other study ID #: IRB00278774
• Status: Completed
• Start date: June 11, 2021
• Est. completion date: March 31, 2024

Study information

• Verified date: April 2024
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV. This will be achieved through a series of remote study visits involving completing surveys about health history, symptoms, mood, quality of life and changes in health, and up to two blood draws from home through the use of a mobile phlebotomy service.

Description:

This is a prospective observational study being conducted to learn about late (2+ weeks or more) effects of COVID-19 in people living with and without HIV. The investigators plan to do this by studying people who have COVID-19 and people who have not had COVID-19, and by studying people living with HIV and people who are HIV-negative. The investigators will investigate the average duration of symptoms after COVID-19, how these symptoms affect quality of life, and what medical complications are common after COVID-19 in people with and without HIV.

Participation involves:

• Participant completion of surveys about themselves, their health history, their quality of life and mood in the recent past, and about COVID-19 or HIV if the participant has a history of either infection. The investigators will ask participants to answer questions in up to 5 follow-up surveys over the course of a year about their symptoms, mood, quality of life, and changes in health. Participants will also complete a series of short tests of thinking, memory, and reaction speed at certain follow-up surveys.

• Up to two visits to the participant's home (or an acceptable location of their choosing) by a phlebotomist. The phlebotomist will collect about 3.5 tablespoons of blood, as well as measure height, weight, and vital signs when laying down and standing up.

This is a fully remote study and all study activities can be done from home or another location of the participant's choosing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 392
• Est. completion date: March 31, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults 18 years of age or older

• Living within the contiguous 48 states

• Groups 1 and 3: self-reported HIV infection

• Groups 2 and 4: self-reported HIV negative

Exclusion Criteria:

• Inability to communicate by telephone in English or Spanish

• Inability to complete required study events

• A first or only diagnosis of COVID-19 5 or more weeks prior to first contact with participant

• Groups 3 and 4: diagnosis of cOVID-19 ever, or participant suspects they had COVID-19 at any time regardless of whether they were tested

Related Conditions & MeSH terms

• COVID-19
• HIV
• Severe Acute Respiratory Syndrome

Intervention

Other:
• No intervention
(observational study)

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland

Sponsors (4)

Lead Sponsor	Collaborator
Johns Hopkins University	amfAR, The Foundation for AIDS Research, Rush University Medical Center, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	New self-reported diagnoses over 12 months after COVID-19 infection	New medical diagnoses after COVID-19 infection.	1, 2, 4, 6 and 12 months
Primary	Change in symptom severity after COVID-19 infection over 12 months after infection	Time to return to usual health and activities, as measured using the Influenza Patient-reported Outcome (Flu-PRO) instrument. The overall score is calculated as the mean across 32 items, and ranges from 0 (symptom free) to 4 (very severe symptoms).	1, 2, 4, 6 and 12 months
Primary	Change in fatigue severity	Presence/absence of fatigue post-symptom onset, severity of fatigue and its effect on activity level as measured using the Fatigue Severity Scale. The Fatigue Severity Scale is a 9-item tool and each item is ranked from 1 (strongly disagree) to 7 (strongly agree). The item scores are added to generate the overall score, ranging from 9 (least severe) to 63 (most severe).	1 and 4 months
Primary	Change in number of COVID-19 symptoms experienced over 12 months after infection	Number of symptoms experienced using Flu-PRO and additional COVID-19 specific symptoms in domains of neuropsychiatry, cardiovascular, and skin. Flu-PRO scores range from 0 (symptom free) to 4 (very severe symptoms).	1, 2, 4, 6 and 12 months
Secondary	Change in mMRC rates of dyspnea	The Modified Medical Research Council (mMRC) instrument will be used to measure dyspnea. The mMRC rates severity of dyspnea on a scale of 0 to 4, 4 indicating the highest level of dyspnea severity.	1 and 4 months
Secondary	Change in cognitive function (learning and memory) as measured by the RAVLT from month 1 to month 4	Learning and memory assessed through the Rey Auditory Verbal Learning Test (RAVLT), in which participants receive a total learning score (range 0-36), a delayed recall score (range 0-12) and a recognition score (range -12 - +12). In all cases, a higher score indicates better recall.	1 and 4 months
Secondary	Change in cognitive function (attention and executive function) as assessed through oral trail tests from month 1 to month 4	Attention and executive function assessed through an oral trail test, in which participants are timed between 0 and 300 seconds. A higher time indicates lower attention and executive function.	1 and 4 months
Secondary	Change in cognitive function (attention and working memory) as assessed through digit span tests from month 1 to month 4	Attention and working memory assessed through a digit span task-forward and backward test. The forward test is scored from 0-16 and the backward test from 0-18, higher scores indicating better attention and memory.	1 and 4 months
Secondary	Change in cognitive function (phonemic and semantic fluency) as assessed through letter and category-guided fluency tests from month 1 to month 4	Phonemic and semantic fluency assessed through a letter-guided and category-guided fluency test. Scores range from 0-100, with a higher score indicating increased fluency.	1 and 4 months
Secondary	Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia	Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting).	1 month
Secondary	Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia	Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting).	4 months
Secondary	Change in PHQ-9 depression symptoms	Self-reported measure of depressive symptoms using The Patient Health Questionnaire (PHQ-9). The PHQ-9 is a 9 item scale with a score range of 1-27 with higher scores indicating severe depression.	1 and 4 months
Secondary	Change in quality of life as assessed using the Short Form-36	Quality of life in the domains of vitality, physical functioning, bodily pain, general health perceptions, physical and emotional and social role functioning, as assessed using the Short Form-36. The Short Form-36 measures physical and mental health using 8 scales. The final score ranges from 0 (worse health status) to 100 (better health status).	1 and 4 months
Secondary	Change in insomnia as assessed using the Insomnia Severity Index from month 1 to month 4	Presence, severity, and patterns of insomnia, and its interference with daily functioning as assessed by the Insomnia Severity Index. The Insomnia Severity Index is a 7 item scale with a score range of 0-28. A higher score indicates severe insomnia.	1 and 4 months
Secondary	Change in anxiety as assessed using the GAD-7 from month 1 to month 4	Self-reported measure of anxiety using The Generalized Anxiety Disorder (GAD-7). The GAD-7 is a 7 item instrument used to measure or assess anxiety disorders. The score range is from 0-21. A higher score indicates severe anxiety.	1 and 4 months
Secondary	Change in overall mental health as assessed using the CAT-MH from month 1 to month 4	Self-reported measures of mental health symptoms (anxiety and depression) using the Computer Adaptive Test-Mental Health (CAT-MH). Scores range from 0-100, with a higher score indicating more severe symptoms.	1 and 4 months